Kallyope
New York City
New York
United States
26 articles with Kallyope
-
Renowned Biopharma Leaders Join Newly Established Kallyope Clinical Development Advisory Board
8/5/2022
Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the formation of its inaugural Clinical Development Advisory Board.
-
Kallyope and Brightseed Enter Collaboration to Identify and Validate Novel Plant-Based Bioactives
7/21/2022
Kallyope and Brightseed have entered a strategic research collaboration to screen plant compounds to identify and validate active agents.
-
Adagio, Aravive, PolyPid, Harpoon, Durect, Nitrase, Kallyope, TScan and many more made major leadership decisions this week.
-
Kallyope, Pioneers in Drug Discovery via the Gut-Brain Axis, Advances Discovery and Development Teams With New Appointments
7/6/2022
Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the promotion of Shirly Pinto , Ph.D., to Chief Scientific Officer and the appointments of Jiajun Liu, Ph.D., as Vice President and Head of Biometrics and Michael Crutchlow, M.D., as Vice President and Head of Translational Medicine.
-
Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery
5/17/2022
Sosei Group Corporation, the international biopharmaceutical company, and New York City-based Kallyope, pioneers in drug discovery involving the gut-brain axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor targets with a goal of creating new drug discovery programs in the area of gastrointestinal diseases.
-
Kallyope, Pioneers in Drug Discovery via the Gut-Brain Axis, Strengthens Senior Leadership Team with Key Appointments
3/16/2022
“With novel compounds in two lead programs now in clinical development, this is an inflection point for Kallyope.
-
Money on the Move: February 9 – 15
2/16/2022
As the market seems to be taking a turn against biotech stock, more companies are opting for private funding instead of going public for the moment. And VC firms are happy to jump in. -
Kallyope focuses on the gut-brain axis, a bi-directional communication between the gastrointestinal tract and the brain.
-
Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth
8/5/2021
Kallyope Inc., a leading biotechnology company focused on identifying and pursuing novel therapeutics involving the gut-brain axis, announced that the Board of Directors has appointed Jay Galeota as President and he will succeed Nancy Thornberry as Chief Executive Officer by October 1, 2021.
-
BioSpace Movers & Shakers, June 4
6/4/2021
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers. -
Kallyope Inc. Appoints Patrick Flanigan as Chief Financial Officer
6/1/2021
Kallyope Inc., a leading biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis, today announced that it has appointed Patrick Flanigan to the position of Chief Financial Officer.
-
Kallyope Inc. Announces $112M Series C Financing to Support First Clinical Trials and Advance Portfolio of Programs Targeting the Gut-Brain Axis
3/25/2020
Kallyope Inc., a leading biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis, today announced a $112 million Series C financing.
-
Kallyope Chief Executive Officer Nancy Thornberry said the company’s journey to becoming a “first-mover in the gut-brain axis space” is coming to fruition.
-
BioSpace Movers & Shakers, Feb. 21
2/21/2020
Biopharma and life sciences companies strengthen their leadership teams and board with this week's Movers & Shakers. -
Kallyope Inc. Appoints Peter Hecht to Board of Directors
2/20/2020
NEW YORK , Feb. 20, 2020 /PRNewswire/ -- Kallyope Inc ., a leading biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis, today announced that Peter Hecht , Ph.D., CEO of Cyclerion Therapeutics, has been appointed to the company's Board of Directors. Prior to joining Cyclerio
-
BioSpace Movers & Shakers, Sept. 6
9/6/2019
Biopharma companies strengthen the C-suite and board of directors with these appointments. -
Kallyope Inc. Appoints Juha Lauren As Chief Business Officer
9/4/2019
Kallyope Inc. announced that it has appointed Juha Lauren, M.D., Ph.D., MBA to the position of Chief Business Officer.
-
BioSpace Movers and Shakers: Feb. 8
2/8/2019
In this week's edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles. -
Kallyope Inc. Appoints Brett Lauring As Chief Medical Officer
2/5/2019
Kallyope Inc., a leading biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, announced that it has appointed Brett Lauring, M.D., Ph.D.
-
Kallyope Inc. Announces $21 Million Expansion of Series B Financing
12/5/2018
Entry of Bill Gates and additional investment from existing syndicate raises Series B total to $87 million